Method of treating patients with hepatorenal syndrome type 1

US10335452B2 · kind B2 · utility

Assignee

• Mallinckrodt Hospital Products IP Unlimited Company · IE

Inventors

• Khurram Jamil · Langhorne, US
• Stephen Chris Pappas · Diemelstraße, US
• Jim Potenziano · Hazelwood, US

Key dates

• Filing date: Oct 22, 2015
• Grant date: Jul 2, 2019
• Expiry date: Apr 5, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2015/1024
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC<4 or >12 cells/μL; HR>90 bpm; and any one of HCO3<21 mmol/L or PaCO2<32 mmHg or >20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.